FDA Adverse Event Malfunction Summary report: N

COBAS® SARS-COV-2 & INFLUENZA A/B

MDR report key: 14518323 · Received May 26, 2022

Report

Report Number
2243471-2022-00508
Event Type
Malfunction
Date Received
May 26, 2022
Date of Event
May 16, 2022
Report Date
June 15, 2022
Manufacturer
ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG
Product Code
QLT
PMA / PMN Number
EUA201779
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

INVESTIGATION IS ONGOING. A FOLLOW-UP REPORT WILL BE FILED UPON THE COMPLETION OF THE INVESTIGATION. (B)(4).

Additional Manufacturer Narrative · 0

FOR BOTH SAMPLES, DELAYED AMPLIFICATION CAN BE OBSERVED FOR THE SARS TARGET, INDICATING THE SAMPLE HAD A LOW VIRAL CONCENTRATION. FURTHER REVIEW OF THE DATASET SHOWS THE CUSTOMER HANDLES A LARGE AMOUNT OF INFLUENZA A AND SARS REACTIVE SAMPLES, IT IS POSSIBLE THAT THE DISCREPANCY, IN THIS CASE, OCCURRED DUE TO CONTAMINATION AT THE CUSTOMER SITE. NO PRODUCT PROBLEM OR SYSTEMIC ISSUE WAS IDENTIFIED. DEVICE CODE WAS UPDATED TO A090806 NON REPRODUCIBLE RESULTS (4029).

Description of Event or Problem · 0

IN LIGHT OF THE COVID-19 PANDEMIC AND THE SUBSEQUENT EMERGENCY USE AUTHORIZATIONS (EUAS) FOR SARS-COV-2 DIAGNOSTIC TESTS, THE AGENCY HAS REQUESTED HEIGHTENED REPORTING BEYOND THE REASONABLY SUGGESTS REQUIREMENTS OF 803 TO INCLUDE ALLEGATIONS OF FALSE POSITIVE OR FALSE NEGATIVE RESULTS INDEPENDENT OF HARM OR MALFUNCTION OR OFF-LABEL USE. PURSUANT TO THE AGENCY¿S INSTRUCTION, WE HEREBY SUBMIT THIS MDR. A CUSTOMER ALLEGED DISCREPANT RESULTS USING THE COBAS® SARS-COV-2 & INFLUENZA A/B TEST ASSAY FOR USE ON THE COBAS® LIAT® SYSTEM. THE ALLEGED SAMPLES INITIALLY GENERATED SARS-COV-2 POSITIVE AND INFLUENZA A POSITIVE RESULTS. THE SAME SAMPLES WERE REPEATED WITH THE SAME DEVICE (SAMPLE 1 WAS REPEATED TWICE, SAMPLE 2 ONLY ONCE) AND GENERATED NEGATIVE RESULTS FOR ALL THREE TARGETS. THE RESULTS WERE NOT REPORTED TO THE PATIENTS. NO APPARENT HARM OR INJURY OCCURRED IN RELATION TO THE EVENT. AN INVESTIGATION IS ONGOING AND RESULTS ARE NOT YET AVAILABLE. PER FDA¿S EUA GUIDANCE, 2 MDRS WILL BE FILED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1851854 COBAS® SARS-COV-2 & INFLUENZA A/B COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES QLT ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG NA 20321X

Patients

Seq Age Sex Outcome Treatment
1 54 YR Female